MOTS-c Mechanisms and Study Models

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This overview summarizes published research on the mitochondrial-derived peptide MOTS-c, focusing on peptide identity, proposed molecular mechanisms, experimental models, measured outcomes, and protocol details explicitly reported in the reviewed sources.

Research scope and peptide identity

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16–amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA region; it is detectable in multiple tissues and in plasma, and reported plasma levels decline with age. ^{[S1] [S2]}

Reviewed literature frames MOTS-c as a mitochondrial-derived signaling peptide implicated in metabolic homeostasis and as a candidate regulator in conditions including insulin resistance, obesity, aging, cardiovascular and inflammatory disorders, and cancer; however, translational/clinical application methods remain undeveloped in the reviewed sources. ^{[S1] [S2] [S3] [S7]}

Mechanisms discussed in cited studies

MOTS-c has been reported to inhibit the folate cycle and associated de novo purine biosynthesis, leading to activation of AMPK as part of its metabolic signaling actions. ^{[S2] [S7]}

Under metabolic stress, MOTS-c translocates to the nucleus and modulates nuclear gene expression in an AMPK-dependent manner; nuclear targets include genes with antioxidant response elements (ARE) and interactions with stress-responsive transcription factors such as NRF2. ^{[S6] [S5]}

In oncology-related experiments, MOTS-c was reported to interact with LARS1, promote LARS1 ubiquitination and proteasomal degradation, and to compete with the deubiquitinase USP7 for LARS1 binding, thereby attenuating USP7-mediated LARS1 deubiquitination. ^[S3]

In a lung ischemia–reperfusion model, a ROS–CK2A–MYH9 signaling axis was described in which CK2A-dependent phosphorylation of MYH9 enabled MOTS-c binding to MYH9–γ‑Actin complexes and MYH9-dependent nuclear translocation, with consequent transcriptional activation of antioxidant genes (e.g., HMOX1, NQO1) identified by RNA-seq and ChIP-seq. ^[S5]

Review articles summarize MOTS-c’s putative downstream regulatory targets and pathways reported across studies, including effects on GLUT4, STAT3, IL‑10, and the AICAR–AMPK axis via folate‑methionine cycle disruption. ^{[S7] [S2]}

Study models and experimental designs

Cellular models: studies include glucose‑restricted cells and hypoxia–reoxygenation/oxidative stress paradigms used to probe MOTS-c nuclear translocation, regulation of ARE-containing genes, and glucose‑uptake assays in cultured skeletal muscle cells. ^{[S6] [S5] [S4]}

Rodent models: mouse models reported include diet-induced obesity and age‑related insulin resistance studies, and a gestational diabetes mellitus (GDM) mouse model produced by short‑term high‑fat diet combined with low‑dose streptozotocin; a rat model was used for lung ischemia–reperfusion injury (LIRI). ^{[S2] [S4] [S5]}

Cancer research encompassed human observational data (reduced MOTS-c in serum and tumor tissues from ovarian cancer patients) alongside exogenous MOTS-c effects in cell-based assays and unspecified in vivo anti‑tumor experiments reported by the same study. ^[S3]

Clinical observational data: one reviewed study reported perioperative clinical sampling (serum MOTS-c increments within 24 h after cardiopulmonary bypass) and correlation with acute respiratory distress syndrome (ARDS) incidence in patients, alongside preclinical rat experiments. ^[S5]

Outcomes measured in the reviewed sources

Metabolic outcomes reported include prevention of diet‑ and age‑dependent insulin resistance, protection from diet‑induced obesity, improvements in glucose metabolism in skeletal muscle, enhanced insulin sensitivity, and increased glucose uptake in vitro. ^{[S2] [S4]}

Reproductive and perinatal outcomes in the GDM mouse model included reductions in hyperglycemia, improvements in glucose and insulin tolerance, decreased birth weight, and reduced offspring mortality in the MOTS-c–treated group reported by the authors. ^[S4]

Oncology outcomes reported were lower MOTS-c levels in ovarian cancer patient serum and tumors (association with poor prognosis), and exogenous MOTS-c inhibition of cancer cell proliferation, migration, invasion, induction of cell‑cycle arrest and apoptosis, and anti‑tumor effects in vivo without reported systemic toxicity. ^[S3]

Oxidative‑stress and lung injury outcomes in the rat LIRI model included endothelial barrier preservation, reduced oxidative damage and inflammation, transcriptional activation of antioxidant genes, and reduced mortality; in the clinical arm, early postoperative increases in serum MOTS-c correlated with ARDS incidence and improved prognostic discrimination. ^[S5]

Cellular molecular outcomes included MOTS-c–dependent changes in nuclear gene expression under metabolic stress, modulation of ARE‑regulated genes, and interaction with NRF2 and other stress‑responsive transcription factors. ^[S6]

Reported study-design and protocol details

MOTS-c administration prevented age‑dependent and high‑fat‑diet‑induced insulin resistance and diet‑induced obesity in mouse studies, with a primary cellular target described as skeletal muscle; mechanistic readouts included folate‑cycle inhibition and AMPK activation, but explicit dosing, route, frequency, and duration details are not reported in the reviewed excerpt. ^[S2]

In the GDM mouse study, a gestational diabetes model was produced by short‑term high‑fat diet combined with low‑dose streptozotocin (STZ); the authors report that MOTS-c was administered daily during pregnancy and that outcomes included maternal glycemia, insulin sensitivity, glucose/insulin tolerance, and reproductive outcomes. ^[S4]

Cellular studies described glucose restriction or hypoxia–reoxygenation as stressors triggering MOTS-c nuclear translocation and gene‑expression changes; specific exposure times, concentrations, or treatment schedules are not reported in the reviewed excerpts. ^{[S6] [S5]}

Ovarian cancer research included human observational comparisons (reduced MOTS-c in serum and tumors, association with prognosis) and exogenous MOTS-c effects in cell assays and in vivo models, but the reviewed excerpt does not provide species, dosing, or administration details for the in vivo anti‑tumor experiments. ^[S3]

In the lung ischemia–reperfusion study, mechanistic experiments implicated ROS‑CK2A–MYH9 signaling for MOTS-c nuclear transport and ChIP‑seq data identified direct interaction with antioxidant gene promoters; clinical samples showed ΔMOTS-c within 24 hours post‑cardiopulmonary bypass with reported prognostic AUC values, but the reviewed excerpt does not state MOTS-c dosing regimens used in the animal interventions. ^[S5]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Most primary intervention data in the reviewed sources are preclinical (cellular and rodent models); interventional human trials are not reported in the reviewed excerpts.
• Explicit experimental details required for replication (dosing amounts, administration routes, exact durations and schedules) are often absent from the reviewed excerpts.
• Some in vivo experimental descriptions in the excerpts lack species or procedural specifics (e.g., the in vivo anti‑tumor model in S3 is not specified in the provided excerpt).
• Mechanistic descriptions span multiple proposed pathways across studies; integration and causality among these pathways remain incompletely reconciled in the reviewed material.

Documentation checklist

• Verify peptide identity and sequence from the primary source before planning experiments.
• Confirm experimental species, model details, and endpoints in the full text of cited studies.
• Obtain explicit dosing, route, frequency, and duration from primary-methods sections rather than abstracts or reviews.
• Differentiate observational human biomarker findings from interventional efficacy data when summarizing outcomes.
• Cross‑check mechanistic claims across multiple studies and consider cell versus in vivo context when interpreting pathways.

Related research supplies

• Cold‑storage specimen labels and inventory logbooks
• Laboratory sample tracking software (LIMS) and barcode labels
• RNAse‑free cryovial storage boxes and organization racks
• Data management templates for study metadata and experimental conditions

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon → (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon → (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

More MOTS-c research

• MOTS-C Human Trials and Exercise Studies
• MOTS-C Mechanisms and Metabolic Research
• MOTS-c Benefits, Uses, and Protocols: What Published Research Reports
• How to Read a Peptide COA Without Getting Fooled
• Peptide Purity vs Identity Testing Explained
• Batch Numbers Explained for Research Supply

Sources and references

1. [S1] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.. Frontiers in endocrinology. 2023. PMID: 36761202. DOI: 10.3389/fendo.2023.1120533
2. [S2] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
3. [S3] Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID: 39321430. DOI: 10.1002/advs.202405620
4. [S4] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research. 2022. PMID: 34798268. DOI: 10.1016/j.phrs.2021.105987
5. [S5] Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.. Redox biology. 2025. PMID: 40403491. DOI: 10.1016/j.redox.2025.103681
6. [S6] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell metabolism. 2018. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008
7. [S7] Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J. MOTS-c Functionally Prevents Metabolic Disorders.. Metabolites. 2023. PMID: 36677050. DOI: 10.3390/metabo13010125
8. [S8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.